Story
Rovi H1 EBITDA Beats on One-Time Gain; Core Business Shows Mixed Results

Spanish pharmaceutical company Laboratorios Rovi SA (BME:ROVI) reported a significant beat on first-half earnings, though the result was heavily skewed by a one-time gain from an acquisition. Operating revenue for the period also surpassed estimates, driven by strong growth in its contract manufacturing division.
Headline Results Driven by Acquisition
Rovi's earnings before interest, taxes, depreciation, and amortization (EBITDA) for the first half of 2026 reached €121.1 million, far exceeding the consensus estimate of €54.1 million, according to its report on Thursday. The outperformance was primarily attributed to a €62.4 million bargain purchase gain related to its acquisition of the Phoenix manufacturing facility on April 1, 2026.
When adjusted for this non-recurring item, the company's underlying EBITDA showed a 10% decrease. Total operating revenue for the first six months grew 9.4% to €344.2 million, beating analyst forecasts of €325.4 million.
Contrasting Divisional Performance
The company's revenue growth was anchored by its Contract Development and Manufacturing Organization (CDMO) business, where sales surged 38% year-over-year to €106.3 million. This was boosted by existing business, new revenue from Bristol Myers Squibb, and a contribution of approximately €45 million from the newly acquired Phoenix facility.
AdIn contrast, the Specialty Pharma division saw flat revenue at €238 million. Key points include:
- Okedi: Sales of the schizophrenia treatment rose 27% to €34 million.
- LMWH: The heparin franchise continued to face headwinds, with sales falling 5% to €125 million due to international partner destocking and pricing pressures.
Outlook and Investment
Rovi maintained its full-year guidance, forecasting low-to-mid single-digit growth in operating revenue. However, the company expects challenges in its heparin business to persist, projecting a mid-single-digit percentage decline in LMWH sales for the full year.
The company also reported a 98% increase in research and development expenses to €33.3 million. Rovi attributed the higher spending to preparations for a Phase III clinical trial of its Letrozole SIE drug, which is scheduled to begin in the third quarter of 2026.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.